Company intelligence / Profile preview

UPPthera

Ownership: Private
Employees: ~19
Development stage: Other

Overview

UPPthera has developed a pipeline of drug candidates using targeted protein degradation technology (PROTACs) with a focus on metabolic diseases and several cancer types. The company has filed at least 15 patents related to protein degradation compounds and has demonstrated success in hit-finding against undruggable targets through collaborations. No late-stage or commercialized products are reported as of now

Therapeutic areas: Metabolic DisordersCardiovascularOncology
Modalities: Proteolysis-targeting chimera therapySmall molecule
Industry: Biotech

Drug pipeline

4 assets

UP1009

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

HitGen Inc. – collaboration for PROTAC research and hit-finding against undruggable targets

Beyond the preview

Go deeper on UPPthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UPPthera.

Explore the full profile